



A Study on Evaluation of Risk Profile and Treatment Pattern of Congestive Heart Failure Patients in a Tertiary Care Hospital

Devatha Venkata Sai Pujitha^{*1}, P. Pratyusha Ande¹, Y. Prapurna Chandra²

¹Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Pidathapolur (V&P), Muthukur (M), SPSR Nellore District – 524 346

²Principal & Professor, Ratnam Institute of Pharmacy, Pidathapolur (V&P), Muthukur (M), SPSR Nellore District – 524 346

ABSTRACT

Heart failure is a complex clinical syndrome that results from a functional or structural heart disorder impairing ventricular filling or ejection of blood to the systemic circulation. It is by definition a failure to meet the systemic demands of circulation. Heart failure remains a highly prevalent disorder worldwide with a high morbidity and mortality rate. The prospective observational study was carried out for a period of 6 months. The study was conducted in cardiology in a tertiary care hospital. A written and informed consent was obtained from the recruited patients. A Total of 135 patients were enrolled in the study. The Leg edema patients were more 40 (29.62 %) as compared to other clinical symptoms. NYHA Class IV patients were more 59 (43.70%) as compared to other NYHA class patients. 7-8 years duration heart failure patients were more 75 (55.55%) as compared to other heart failure durations. Asthma comorbid patients were more 48 (35.55 %) as compared to other comorbidities. Abnormal ECG patients were more 103 (76.29%) as compared to normal ECG patients. Antiplatelets prescribed patients were more 42 (31.11%) as compared to other prescribed drugs. The incidence of heart failure is slightly higher in males. A combination therapy proves to be more effective than a single drug. A combination of up to 5 drugs are in practice, the most common being Four-drug and Three-drug therapy. The Prescription of generic drugs reduces the patients' burden making it more affordable and also the chance of survival for long time depends on absence or presence of co-morbidities.

Keywords: Heart failure, ventricular filling, circulation, co-morbidities, Leg edema, Antiplatelets.

ARTICLE INFO

Corresponding Author

Devatha Venkata Sai Pujitha
Department of Pharmacy Practice,
Ratnam Institute of Pharmacy,
Pidathapolur (V&P), Muthukur (M), Nellore-524346

Article History

Received : 22 July 2023
Revised : 04 Aug 2023
Accepted : 20 Aug 2023
Published : 23 Sept 2023

Copyright© 2023 The Contribution will be made Open Access under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0>) which permits use, distribution and reproduction in any medium, provided that the Contribution is properly cited and is not used for commercial purposes.

Citation: Devatha Venkata Sai Pujitha, et al. A Study on Evaluation of Risk Profile and Treatment Pattern of Congestive Heart Failure Patients in a Tertiary Care Hospital. A. J. Med. Pharm. Sci., 2023, 11(1): 35-39.

CONTENTS

1. Introduction.....	35
2. Methodology.....	36
3. Results and Discussion.....	36
4. Conclusion.....	38
5. References.....	38

1. Introduction

Heart failure (HF) is a clinical syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood¹⁻⁵. The most common cause for HF is reduced left ventricular myocardial function; however, dysfunction of the pericardium, myocardium, endocardium, heart valves or great vessels alone or in combination is also associated with HF. Some of the major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related

dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. The goal of therapy for chronic CHF is to improve symptom management and quality of life, decrease hospitalizations, and decrease overall mortality associated with this disease. The goal of pharmacologic therapy is to give all indicated agents rather than single agents because the aggregate effect

of these therapies is better than monotherapy from any of the agents. The primary combination therapy for HFrEF includes diuretics, a renin-angiotensin system inhibitor (such as an angiotensin receptor neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin II receptor blockers and a beta-blocker. The combination of hydralazine and nitrate is an alternative to an angiotensin system blocker for primary therapy if ACE inhibitor, ARNI, and ARB therapies are contraindicated⁶⁻¹⁰. The nitrate and hydralazine combination is also indicated to reduce mortality and morbidity in African American patients with symptomatic HFrEF, currently receiving optimal medical therapy. The combination therapy of ARB-ARNI significantly reduced cardiovascular death and HF hospitalizations when compared to ACE inhibitors alone.

2. Methodology

Study Design: It was Prospective observational study.

3. Results and Discussion

Table 1: Age In our study 25-30 years age patients were 36(26.66%), 31-39 years age patients were 27(20%), 40-45 years age patients were 60(44.44%), 46-56 years age patients were 12(8.88 %).

S.No	Age	Total N=135	Percentage (%)
1.	25-30	36	26.66
2.	31-39	27	20
3.	40-45	60	44.44
4.	46-56	12	8.88
	Total	135	

Table 2: Gender In our study Males patients were 55(40.74%), Female patients were 80(59.25%).

S.No	Gender	Total N=135	Percentage (%)
1	Males	55	40.74
2	Female	80	59.25
	Total	135	

Table 3: Diet Vegetarian patients were 66 (48.88%), Non Vegetarian patients were 69 (51.11%).

S.No	Diet	Total N=135	Percentage (%)
1.	Vegetarian	66	48.88
2.	Non Vegetarian	69	51.11
	Total	135	

Table 4: Education Primary education patients were 23(17.03%), Secondary education patients were 19(14.07%), Graduation education patients were 93(68.88%).

S.No	Education	Total N=135	Percentage (%)
1.	Primary	23	17.03
2.	Secondary	19	14.07
3.	Graduation	93	68.88
	Total	135	

Table 5: Clinical symptoms Clinical symptoms includes Shortness of Breath patients were 31(22.96%), Orthopnoea patients were 25(18.51%), Nocturnal Dysnoea patients were 39(28.88%), Leg edema patients were 40 (29.62 %).

S.No	Clinical symptoms	Total N=135	Percentage (%)
1.	Shortness of Breath	31	22.96
2.	Orthopnoea	25	18.51
3.	Nocturnal Dysnoea	39	28.88
4.	Leg edema	40	29.62
	Total	135	

Table 6: Risk factors Risk factors of heart failure includes Acute coronary syndrome patients were 50(37.03%), Thyroid problems patients were 10(7.40%), Valvular heart disease patients were 25(18.51%), Dilated Cardiomyopathy patients were 18(13.33%), Hypertension patients were 19(14.07%), Smoking and alcohol patients were 13(9.62%).

S.No	Risk factors	Total N=135	Percentage (%)
1	Acute coronary syndrome	50	37.03
2	Thyroid problems	10	7.40
3	Valvular heart disease	25	18.51
4	Dilated Cardiomyopathy	18	13.33
5	Hypertension	19	14.07
6	Smoking and alcohol	13	9.62
	Total	135	

Table 7: NYHA class The Clinical symptoms of heart failure includes Class I patients were 20(14.81%), Class II patients were 19(14.07%), Class III patients were 37(27.40%), Class IV patients were 59 (43.70%).

S.No	Clinical symptoms	Total N=135	Percentage (%)
1	Class I	20	14.81
2	Class II	19	14.07
3	Class III	37	27.40
4	Class IV	59	43.70
	Total	135	

Table 8: Duration of Heart failure The duration of hypertension includes 1-4 years patients were 41(30.37%), 5-6 years patients were 19(14.07%), 7-8 years patients were 75 (55.55%).

S.No	Duration	Total N=135	Percentage (%)
1	1-4 years	41	30.37
2	5-6 years	19	14.07
3	7-8 years	75	55.55
	Total	135	

Table 9: Co morbidities The Comorbidities includes Renal failure patients were 14(10.37),Diabetes mellitus patients were 21(15.55), Hypertension patients were 19(14.07), Stroke patients were 33(24.44), Asthma patients were 48 (35.55).

S.No	Comorbidities	Total N=135	Percentage (%)
1	Renal failure	14	10.37
2	Diabetes mellitus	21	15.55
3	Hypertension	19	14.07
4	Stroke	33	24.44
5	Asthma	48	35.55
	Total	135	

Table 10: LVEF (%) The LVEF (%) includes 25-32 % LVEF patients were 45(33.33%),33-45% LVEF patients were 39(28.88%),46-51% LVEF patients were 51 (37.77%).

S.No	LVEF (%)	Total N=135	Percentage (%)
1	25-32	45	33.33
2	33-45	39	28.88
3	46-51	51	37.77
	Total	135	

Table 11: Prescribing pattern of heart failure drugs

S.No	Prescribing pattern of NSAID'S	Total N=135	Percentage (%)
1	ACE inhibitors	13	9.62
2	Beta blockers	21	15.55
3	Antiplatelet Agents	22	16.29
4	Diuretics	12	8.88
5	Digoxin	10	7.40
6	Statins	15	11.11
7	Antiplatelets	42	31.11
	Total	135	

Table 12: ECG The normal ECG patients were 32(23.70%) and abnormal ECG patients were 103 (76.29%).

S.No	ECG	Total N=135	Percentage (%)
1	Normal	32	23.70
2	Abnormal	103	76.29
	Total	135	

Discussion

- In our study 40-45 years age patients were more 60(44.44%) as compared to other ages.
- Female patients were more 80(59.25%) as compared to males.
- Non Vegetarian patients were more 69 (51.11%) as compared to Vegetarian patients.
- Leg edema patients were more 40 (29.62 %) as compared to other clinical symptoms.
- Acute coronary syndrome patients were more 50(37.03%) as compared to other clinical risk factors¹¹⁻¹⁶.
- NYHA Class IV patients were more 59 (43.70%) as compared to other NYHA class patients.
- 7-8 years duration heart failure patients were more 75 (55.55%) as compared to other heart failure durations.
- Asthma comrbid patients were more 48 (35.55) as compared to other comorbidities.
- 46-51% LVEF patients were more 51 (37.77%) as compared to other LVEF values.
- Abnormal ECG patients were more 103 (76.29%) as compared to normal ECG patients.
- Antiplatelets prescribed patients were more 42 (31.11%) as compared to other prescribed drugs.

4. Conclusion

Heart Failure is caused due to various underlying diseases among which, Ischemic Heart Disease and dilated cardiomyopathy are most common followed by Hypertension and Diabetes, a few caused by Rheumatic Heart Disease¹⁸⁻²⁰. In our study 40-45 years age patients were more 60(44.44%) as compared to other ages. NYHA Class IV patients were more 59 (43.70%) as compared to other NYHA class patients. Antiplatelets prescribed patients were more 42 (31.11%) as compared to other prescribed drugs.

5. References

- [1] Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am CollCardiol*. 1993;22(4 Suppl A):6A–13A. doi: 10.1016/0735-1097(93)90455-A.
- [2] Tsuyuki RT, McKelvie RS, Arnold JM, Avezum A, Baretto ACP, Carvalho AC. et al. Acute precipitants of congestive heart failure exacerbations. *Arch Intern Med*. 2001; 161(19): 2337–42.
- [3] Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR. et al. Coronary artery disease as the cause of incident heart failure in the population. *Eur Heart J*. 2001;22(3):228–36.
- [4] Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG. et al. 2009 focused

update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*. 2009;119: e391–479.

- [5] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*. 1991;325(5):293–302.
- [6] Baskota M, Rao BS, Shakya R. Study on the prescribing patterns of drugs used in heart failure. *Kathmandu University Journal of Science, Engineering, and Technology*. 2006;2(1):1–10.
- [7] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators [comment] *N Engl J Med*. 1999; 341: 709–17.
- [8] The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med*. 1997;336:525–33.
- [9] Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ. et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors RADIANCE Study. *N Engl J Med*. 1993;329:1–7.
- [10] Cleland JG, Tendera M, Adamus J, Freemantle N, Polonsky L, Taylor J. et al. The perindopril in elderly people with chronic heart failure (pep-CHF) study The PEP investigators. *Eur Heart J*. 1999;1(3):211–7.
- [11] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. et al. ESC Scientific Document Group 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37:2129–2200.
- [12] Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS. et al. Beta-Blockers in Heart Failure Collaborative Group Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-

- level analysis of double-blind randomized trials. *Eur Heart J*. 2018;39:26–35.
- [13] Choi KH, Choi JO, Jeon ES. et al. Guideline-Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient-Pooled Analysis From the Kor HF and Kor AHF Registries. *J Am Heart Assoc*. 2018; 7(21): e009806.
- [14] Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. *N Engl J Med*. 1999;341:910–11.
- [15] Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. *Am J Cardiol*. 2003;91:2De8D.
- [16] Allen LA, O'Connor CM. Management of acute decompensated heart failure. *CMAJ*. 2007; 176(6): 797–805.
- [17] Seferović PM, Vardas P, Jankowska EA, et al. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. *Eur J Heart Fail*. 2021;23:906–914.
- [18] Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. *Int J Heart Fail*. 2021;3:224–236.
- [19] Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. *Am Heart J*. 2000;139:72–77.
- [20] Hershberger RE, Cowan J, Jordan E, Kinnamon DD. The complex and diverse genetic architecture of dilated cardiomyopathy. *Circ Res*. 2021; 128: 1514–1532.